Showing results (211-220 of 432) with videos related to

Sort By:
Pageof 44
Haematologica|October 8, 2008
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblastsGhulam J Mufti, John M Bennett, Jean Goasguen, et al.
Haematologica|April 1, 2014
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)Leonie Saft, Mohsen Karimi, Mehran Ghaderi, et al.
Blood Advances|September 7, 2021
Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologistsIgor Stojkov, Annette Conrads-Frank, Ursula Rochau, et al.
Leukemia|June 14, 2018
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDSPierre Fenaux, Valeria Santini, Maria Antonietta Aloe Spiriti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and olderClaude Gardin, Sylvie Chevret, Cécile Pautas, et al.
Cancer|April 8, 2015
Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL groupThorsten Braun, Sophie Cereja, Sylvie Chevret, et al.
Journal of Clinical Medicine|January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 TrialEsther Natalie Oliva, Uwe Platzbecker, Guillermo Garcia-Manero, et al.
Haematologica|July 21, 2018
Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL groupLionel Adès, Xavier Thomas, Agnes Guerci Bresler, et al.
Haematologica|October 14, 2011
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des MyelodysplasiesLionel Adès, Fabien Le Bras, Marie Sebert, et al.
Blood|May 22, 2010
Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remissionOlivier Nibourel, Olivier Kosmider, Meyling Cheok, et al.
Pageof 44